INTRODUCTION
============

Malaria, the parasitic disease of the red blood cell caused by *Plasmodium sp*, kills more than one million children each year in Africa alone ([@B6]). The strong selective pressure that malaria exerts has been shaping the human genome for at least 6,000 years ([@B12]) and the disease is the driving force behind several genetic disorders, such as the sickle cell trait, glucose-6-phosphate dehydrogenase deficiency and thalassemia ([@B6]). The single nucleotide polymorphisms (SNPs) responsible for the above traits afford protection against malarial parasites and hence have been maintained in some human populations by a mechanism of balancing selection ([@B2]). In addition to the erythrocyte variants, SNPs in genes that modulate the immune response have been also reported to confer resistance to malaria ([@B6]).

Different human populations may have developed independent and different responses to malaria, but the bulk of studies on the genetics of those responses has been performed in Africa, where remarkable examples of differences in protection can be found ([@B6]). Most of the sub-Saharan African populations, for instance, are completely resistant to the malaria caused by *P. vivax*, whereas populations outside Africa are not. The protection in Africans is believed to be associated with a SNP in the promoter region of the *FY* gene ([@B18]), which abolishes transcription in erythrocytes and consequently prevents the parasite from invading the red blood cells ([@B8]).

Malaria is also endemic in South Asian countries such as India, Nepal, Bhutan, and Sri Lanka, ([@B4]). In Nepal, for example, the WHO reported 4,637 cases in 2004, from a population of 27.3 million; 7.9% of the cases were caused by *P. falciparum* (<http://w3.whosea.org/en/Section10/Section21/Section340.htm>). However, the probable number of cases was judged to be an order of magnitude higher than the reported number, leading to an estimated incidence of approximately 0.17% per year. Few studies of resistance have been performed in this region ([@B21]). The lack of data on malaria-protective genes in South Asia is surprising since some ethnic groups, such as the Tharu in Nepal, have long been known to be resistant to the disease ([@B16]). A large part of Nepal consists of mountains where malaria cannot be transmitted ([@B3]), but the southern part of the country, the Terai area where malaria cases are concentrated is flat and exposed to the malaria parasites *P. vivax* and *P. falciparum* ([@B15]).

The incidence of malaria in the Terai has restricted the settlement of the region, but nevertheless it has been inhabited by aboriginal groups since pre-historical times ([@B20]). The populations designated 'lowland' here fall into this category, as far as is known. Besides these lowland inhabitants, there are other Nepalese populations who live up in the hills but visit low lying areas in the Terai during the daytime when the mosquitoes that spread malaria do not bite -- a pattern referred to as "diurnal uphill-downhill" migration ([@B20]). The Terai has also experienced migration from other parts of the country during the Rana period, which started in 1856 and led to deforestation of the region, and from the 1950s with the implementation of a malaria eradication program ([@B16]). Such populations were not sampled in this study.

It has been proposed that the high frequency of thalassemia among some Nepalese populations such as the Tharu and the Danuwar could explain their biological resistance to malaria ([@B9]; [@B13]). However, the involvement of other genes in this protection and the resistance in other populations have not been thoroughly investigated ([@B7]). We have therefore examined the frequency of seven malaria-protective SNPs in 928 healthy individuals from different parts of Nepal in order to investigate whether known African protective alleles also confer resistance in Asia. By comparing populations living successfully in malaria-endemic lowland regions, and thus resistant to the disease, with those from malaria-free highland regions, we could investigate the contribution these alleles make to malaria resistance in this region.

SUBJECTS AND METHODS
====================

Study subjects and PCR amplification
------------------------------------

The sample consisted of 928 healthy individuals representing different groups identified on the basis of ethnicity, language and geography within Nepal ([@B20]; [@B5]). All samples were collected in accordance with the Human Genome Diversity Project Ethics Protocol and with the appropriate approval and cooperation of local institutions. The research aims of the project were explained in Nepali to each individual and informed consent forms in both Nepali and English were signed ([@B20]; [@B5]). Samples were then anonymised before export and DNA analysis. During sampling, care was taken to sample long-term residents. Rural, rather than urban, areas were sampled, both parents belonged to the same ethno-linguistic group as the donor, and the donor\'s name was characteristic of the ethnic group and the geographic location within Nepal.

Seven SNPs located in the genes *HBB*, *FY*, *G6PD*, *TNFSF5*, *TNF*, *NOS2*, and *FCGR2A* were selected based on previous reports of association with malaria resistance in non-South Asian patients ([@B6]) and amplified by Polymerase Chain Reaction (PCR). Primers were designed with Primer3 (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi>), screened for primer-dimer and hairpin interactions using AutoDimer ([@B19]) and combined into two multiplex reactions, M1 (*FY*, *TNFSF5*, *G6PD* and *HBB*) and M2 (*TNF*, *NOS2* and *FCGR2A*) ([Table 1](#T1){ref-type="table"}). Amplification was carried out in a 25 μl volume containing 10 ng genomic DNA, 150 μM of deoxynucleotide triphosphates (dNTPs; Amersham Biosciences), 1 mM MgCl~2~, 2.0 U of Platinum *Taq* DNA Polymerase (Invitrogen, Paisley, UK) with 1 x buffer, and the primer final concentrations shown in [Table 1](#T1){ref-type="table"}. The thermal conditions in an MJ Research DNA Engine Tetrad™ (Genetic Research Instrumentation, Braintree, UK) were as follows: Denaturation at 94°C for 15 min, followed by 15 cycles of touchdown PCR: 94°C for 30 sec, 65°C for 30 sec, 72°C for 45 sec, with a 1°C decrease in annealing temperature in every cycle, and then 17 cycles of standard PCR (94°C for 30 sec, 50°C for 30 sec, 72°C for 45 sec), followed by extension at 72°C for 7 min and storage at 4°C. Unincorporated dNTPs and primers were removed by mixing 15 μl of these PCR products with a 5 μl volume containing 2.0 U of Exonuclease I (USB, Cleveland, USA) and 5.0 U of Shrimp Alkaline Phosphatase (or SAP; USB) for 1 hr at 37°C followed by incubation at 80°C for 15 min.

###### 

PCR primer sequences for the multiplex amplification of 7 SNPs previously associated with resistance to malaria

  SNP ID          Gene                                     Base Change[a](#TF1_1){ref-type="table-fn"}   PCR primers (final concentration)               Amplicon size (bp)
  --------------- ---------------------------------------- --------------------------------------------- ----------------------------------------------- --------------------
  rs334           *HBB*                                    T/A                                           F: 5′--AGTCAGGGCAGAGCCATCTA--3′ (0.05 μM)       157
                                                                                                         R: 5′--CTCACCACCAACTTCATCCA--3′ (0.05 μM)       
  rs2814778       *FY*                                     C/T                                           F: 5′--TCACCCTGTGCAGACAGTTC--3′ (0.1 μM)        226
                                                                                                         R: 5′--CAAAACAGGAAGACCCAAGG--3′ (0.1 μM)        
  rs5030868       *G6PD*[b](#TF1_2){ref-type="table-fn"}   T/C                                           F: 5′--TGCAGCTGTGATCCTCACTC--3′ (0.05 μM)       388
                                                                                                         R: 5′--AGGTGGAGGAACTGACCTTG--3′ (0.05 μM)       
  rs3092945       *TNFSF5*                                 C/T                                           F: 5′--GATTTGCCCAAGGCTCATAG--3′ (0.1 μM)        300
                                                                                                         R: 5′--AAAAGCATGCTGATGGTTATTAAA--3′ (0.01 μM)   
                                                                                                                                                         
  **rs1800629**   *TNF*                                    G/A                                           F: 5′--CAAACACAGGCCTCAGGACTC--3′ (0.08 μM)      518
                                                                                                         R: 5′--AGGGAGCGTCTGCTGGCTG--3′ (0.08 μM)        
  rs1800482       *NOS2*                                   C/G                                           F: 5′--CATGGTGGCTAACCCTTGTAA--3′ (0.08 μM)      227
                                                                                                         R: 5′--CTGCTCATTGCAACTTCTGC--3′ (0.08 μM)       
  **rs1801274**   *FCGRIIA*                                C/T                                           F: 5′--CCAGAATGGAAAATCCCAGA--3′ (0.08 μM)       163
                                                                                                         R: 5′--CAGACTCCCCATACCTTGGA--3′ (0.08 μM)       

the protective allelic state is listed first.

both forward and reverse PCR primers had been previously published ([@B17])

The SNPs in bold were polymorphic in the studied population.

Mini-sequencing reaction and capillary electrophoresis
------------------------------------------------------

Seven mini-sequencing primers were selected from either the reverse or forward direction for each locus and screened for hairpin and primer-dimer interactions as described above. The SNPs at *FY*, *TNFSF5*, *G6PD* and *HBB* (multiplex 1) and those at *TNF*, *NOS2* and *FCGR2A* (multiplex 2) were genotyped in two separate mini-sequencing reactions using the ABI Prism^®^ SNaPshot™ kit (Applied Biosystems, Foster City, USA). The reactions were carried out in a total volume of 5 μl containing 2.5 μl of SNaPshot Multiplex Ready Reaction mix, 1.0 μl of the minisequencing primer mix 1 or 2 ([Table 2](#T2){ref-type="table"}), 1.0 μl of deionized water and 0.5 μl of the purified PCR products. Thermal cycling conditions consisted of 25 cycles of 96°C for 10 sec, 50°C for 5 sec, and 60°C for 30 sec. Unincorporated labeled dideoxynucleotide triphosphates (ddNTPs) were removed by adding 1U of SAP to the minisequencing products, and incubated at 37°C for 1 hr, followed by 15 min at 80°C. One tenth of the purified minisequencing reaction (0.5 μl) was mixed with 9.0 μl Hi--Di formamide and 0.5 μl GeneScan-120 LIZ size standard (Applied Biosystems, Warrington, UK). This mixture was then denatured for 2 min at 96°C and analysed in the ABI PRISM 3100 Genetic Analyzer, using filter set E5 and a 36 cm capillary array filled with POP4 polymer (Applied Biosystems). Allele scoring was performed using GeneMapper 3.0 software (Applied Biosystems).

###### 

Minisequencing primers for the multiplex detection of 7 SNPs previously associated with resistance to malaria

  Gene               Sequencing primers (final concentration in the primer mix)              Length (nt)
  ------------------ ----------------------------------------------------------------------- -------------
  *HBB*              5′--ATGGTGCACCTGACTCCTG--3′ (0.1 μM)                                    19
  *FY*               5′--GACTGACTCTCATTAGTCCTTGGCTCTTA--3′ (0.6 μM)                          29
  *[G6PD]{.ul}*      5′--GACTGACTGACTGACATCTGGTCCTCACGGAACAGGGAG--3′ (0.05 μM)               39
  *TNFSF5*           5′--GACTGACTGAGACTGACTATTTTCCCTATTCTGAACTGTTACATCAGCA--3′ (0.7 μM)      49
                                                                                             
  *TNF*              5′--GACTGACTGACTGACTGACTGAGACTGAAGGCAATAGGTTTTGAGGGGCATG--3′ (0.6 μM)   52
  *NOS2*             5′--GACTGACTGAGACTGACAGATCACTTGAGCTTCAGAGTTCGA--3′ (0.4 μM)             42
  *[FCGRIIA]{.ul}*   5′--TGGAGAAGGTGGGATCCAAA--3′ (0.1 μM)                                   20

**Note:** The mini-sequencing primers for the underlined genes were chosen based on the reverse strand and the scored alleles should be the reverse of those shown in [Table 1](#T1){ref-type="table"}.

Data analyses
-------------

Allele and genotype frequencies were obtained by direct counting and differences in allele frequencies were assessed by means of Fisher\'s exact test in the 928 healthy individuals residing in either lowlands (n = 146) or highlands (n = 782) of Nepal. The hypothesis of Hardy-Weinberg equilibrium (HWE) was tested using the approach of Guo and Thompson implemented in Arlequin 2.0 ([@B14]). Conventional pairwise F~st~ distances and analysis of molecular variance (AMOVA) were obtained with Arlequin for the 18 populations whose sample size was greater than 20. For AMOVA, populations were pooled according to whether they reside in lowlands or highlands, and the results were then compared with no grouping. Differences in allele frequencies for the 18 populations were assessed by the Mann-Whitney test using SPSS v 14.0.

RESULTS AND DISCUSSION
======================

We typed seven SNPs in genes previously associated with protection to malaria in Africa ([@B6]), namely *HBB*, *FY*, *G6PD*, *TNFSF5*, *TNF*, *NOS2*, and *FCGR2A*, in 928 healthy individuals from Nepal, a country in Asia where the disease is also endemic. Out of the seven SNPs, five were found to be fixed for the non-protective allele at *HBB*, *FY*, *G6PD*, *TNFSF5* and *NOS2* ([Table 1](#T1){ref-type="table"}). Surprisingly, the protective allele at rs5030868 in *G6PD* which has been observed in other South Asian countries, such as India ([@B1]) was absent from the large Nepalese sample examined here. The non-protective allele at these SNPs is also fixed in all HapMap samples, with the exception of Africans (<http://www.hapmap.org/index.html.en>), and also in non-Africans from dbSNP (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp>). On the other hand, the SNPs in *TNF* (rs1800629) and *FCGR2A* (rs1801274) were polymorphic in the Nepalese population, and the protective alleles were found at an overall frequency of 93% and 27%, respectively. In the combined Nepalese sample, the genotype frequencies at these SNPs were found to depart significantly from HWE (*p*\<0.0001).

We then investigated the correlation of these two SNPs with the regions in Nepal that are exposed to malaria or not, i.e. lowlands and highlands. The frequency of the protective allele at *TNF* in our entire data set (n=928) was 89% in the lowlands and 94% in the highlands, and the difference in this allele frequency was statistically significant (Fisher\'s exact test, *p*=0.02). In combined populations from the highlands a significant departure from HWE was observed (*p*=0.0002), whereas in the lowlands the hypothesis of random association of alleles was not rejected (*p*=0.0679). For *FCGRIIA*, no significant difference was seen in the frequency of the protective allele between lowland (22%) and highland (28%) populations; the genotype frequencies in the combined populations from the highlands departed from HWE (*p*=0.001) but those in the lowlands did not (*p*=0.326). Subsequently we looked at the correlation of these SNPs with malaria exposure in the 18 individual populations of Nepal which had a sample size greater than 20 (n=586, [Figure 1](#F1){ref-type="fig"}). No significant departures from HW expectations were found in individual populations ([Table 2](#T2){ref-type="table"}), which suggested that the *p* values obtained above reflected population subdivision present in the country.

![Distribution of malaria-protective alleles (black sectors) in Nepal. Red lines indicate populations from malaria-endemic lowland regions, black lines from malaria-free highland regions. A) rs1800629 (*TNF*), B) rs1801274 (*FCGRIIA*).](jmgm-02-101-g001){#F1}

Then, it was surprising to see among the individual populations that for *TNF* (rs1800629), four out of five populations living in malarial areas actually had lower frequencies of the protective allele than populations living in malaria-free regions ([Figure 1](#F1){ref-type="fig"}A). Two groups showed frequencies greater than 25% of the non-protective allele at rs1800629, the Sherpa and the Danuwar ([Figure 1](#F1){ref-type="fig"}A, [Table 3](#T3){ref-type="table"}). Both of them live in the malaria-free highlands of Nepal, which could explain the unconstrained higher frequency of the non-protective allele. However, it is striking that some of the other highland populations are fixed or almost fixed for the protective allele ([Figure 1](#F1){ref-type="fig"}A, [Table 3](#T3){ref-type="table"}). For *FCGRIIA* (rs1801274), a similar lack of association of the protective allele with malarial regions of Nepal was observed ([Fig. 1](#F1){ref-type="fig"}B). A frequency greater than 52% of the protective allele was seen in two populations living at high altitude, High Caste Newar and Chantyal, whereas this allele was found to be as rare as 18% in Kumal and Majhi Bote, two groups exposed to the disease ([Figure 1](#F1){ref-type="fig"}B, [Table 3](#T3){ref-type="table"}). However, the differences in allele frequencies between the highland and lowland populations were not statistically significant at either *TNF* or *FCGRIIA* (Mann-Whitney U test). This lack of correlation between the protective alleles at both *TNF* and *FCGRIIA* and the distribution of malaria suggests that malaria did not select for these alleles in Nepal.

###### 

Genotype and allele[a](#TF3_1){ref-type="table-fn"} frequencies in 18 populations from lowlands and highlands of Nepal

  Population                                    n    Genotype                                                                                          
  --------------------------------------------- ---- ---------- ------ ------ ------ ------------------------------------- ------ ------ ------ ------ ------
  Baram                                         38   1.00       1.00                 N.A[c](#TF3_3){ref-type="table-fn"}   0.37   0.14   0.46   0.40   0.07
  Chantyal                                      23   0.89       0.79   0.21          1.00                                  0.50   0.25   0.5    0.25   0.08
  **Chepang**[d](#TF3_4){ref-type="table-fn"}   27   1.00       1.00                 N.A                                   0.20   0.04   0.32   0.62   1.00
  Danuwar                                       30   0.70       0.49   0.42   0.09   0.69                                  0.05          0.10   0.90   1.00
  **Dhimal**                                    22   0.89       0.79   0.21          1.00                                  0.27   0.08   0.20   0.72   0.63
  Dura                                          35   0.96       0.92   0.08          1.00                                  0.31   0.10   0.43   0.47   1.00
  Ghale                                         25   0.98       0.96   0.04          1.00                                  0.16          0.13   0.70   1.00
  Gurung                                        46   0.93       0.86   0.14          1.00                                  0.41   0.17   0.48   0.35   0.23
  High Caste Newar                              29   1.00       1.00                 N.A                                   0.52   0.27   0.50   0.23   1.00
  **Kumal**                                     25   0.88       0.77   0.21   0.02   0.29                                  0.18   0.03   0.30   0.67   1.00
  Magar                                         45   0.94       0.88   0.11   0.01   0.11                                  0.21   0.05   0.33   0.62   0.38
  **Majhi Bote**                                27   0.85       0.72   0.26   0.02   0.45                                  0.19   0.04   0.31   0.65   0.19
  Newar                                         50   0.99       0.98   0.02          1.00                                  0.33   0.11   0.44   0.45   0.75
  Sherpa                                        24   0.75       0.56   0.38   0.06   0.59                                  0.23   0.05   0.35   0.60   0.56
  Tamang                                        48   0.97       0.94   0.06          1.00                                  0.26   0.07   0.38   0.55   1.00
  Thakali                                       29   0.93       0.86   0.13   0.01   0.10                                  0.31   0.09   0.43   0.48   1.00
  **Tharu**                                     34   0.85       0.72   0.25   0.03   0.12                                  0.25   0.06   0.38   0.56   0.39
  Wambule                                       29   1.00       1.00                 N.A                                   0.16   0.03   0.26   0.71   0.11

Frequency of the protective alleles G and C at *TNF* and *FCGRIIA*, respectively

*p* values after testing for departure from Hardy-Weinberg equilibrium (random association of alleles in diploid individuals)

N.A. not applicable

The populations in bold live in the malarial lowlands of Nepal. The remaining groups live in regions of high altitudes, which are malaria-free

Finally, we assessed whether or not the inter-population diversity between groups living in malaria-free regions and those exposed to the disease varied significantly. By means of AMOVA, we found that 91% and 95% of the entire variation at rs1800629 (*TNF*) and rs1801274 (*FCGRIIA*), respectively, was observed within populations. In contrast, the amount of variation between groups was zero for *TNF* and 0.54% (*p*=0.22; not significantly different from zero) for *FCGRIIA*, whereas the F~st~ (distance between populations among groups) was 9% for *TNF* and 5% for *FCGRIIA*. The observed low F~st~ values and the AMOVA analyses further support our conclusion that it is unlikely that selection by malaria has significantly influenced the frequencies of the protective alleles at *TNF* and *FCGRIIA* in Nepal.

Although genes such as *G6PD*, *TNF* and *FCGRIIA* have previously been associated with malaria resistance in parts of Asia ([@B1]; [@B7]; [@B10]; [@B21]), the disease did not play an important role in selecting or maintaining the protective alleles of these genes in the populations that we have examined in Nepal. Recent migration and admixture could equalise gene frequencies between populations, but both our sampling strategy and the high differentiation between populations observed at other loci (results not shown) lead us to conclude that such factors cannot explain our results. It is possible that selection for other functions of these genes has dominated in Nepal, but perhaps more likely either that the populations and disease have not co-existed in this region for long enough for malaria to influence allele frequencies detectably, or that genetic drift dominates to such an extent in these small populations ([@B11]) that it overwhelms any selective force by malaria. The investigation of additional SNPs and genes that may contribute to malaria resistance, especially those involved in the human immune response, could help to distinguish between the above hypotheses.

We thank all DNA donors, the organisations and volunteers in Nepal, who gave us their assistance; Mark A Jobling and Emma Parkin for comments on the manuscript, Cara Woodwark for bioinformatics support, and three referees for suggesting improvements to the manuscript. The research was conducted in association with the Centre for Nepal and Asian Studies (CNAS) at Kirtipur under the Bilateral Agreement for Academic Cooperation between Tribhuvan University and Leiden University, as part of the European Science Foundation EUROCORES Programme OMLL. CPC and DRC-S were supported by the Arts and Humanities Research Board and the EC Sixth Framework Programme under Contract no. ERAS-CT-2003-980409. TK, GvD, PdK were supported by the NWO (Netherlands Organisation for Scientific Research) grant 231-70-001, and CT-S was supported by The Wellcome Trust, UK.

The authors declared no competing interests.

HWE

:   Hardy-Weinberg equilibrium

SAP

:   Shrimp Alkaline Phosphatase

SNP

:   Single Nucleotide Polymorphism

ELECTRONIC-DATABASE INFORMATION
===============================

1.  <http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi>

2.  <http://w3.whosea.org/en/Section10/Section21/Section340.htm>

3.  <http://www.hapmap.org/index.html.en>

4.  <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp>
